Dry powder inhaler flow rate performance studies being suggested by FDA, especially for newer devices.
DRY POWDER INHALER FLOW RATE PERFORMANCE STUDIES are being suggested by FDA, especially for newer inhaler designs, Division of Pulmonary Drug Products Medical Officer Babatunde Otulana, MD, said at a Jan. 14 Drug Information Association meeting on DPIs in Washington D.C. The studies suggested by Otulana are in addition to the studies outlined in FDA's 1994 Points to Consider on Dry Powder Inhalers ("The Pink Sheet" July 18, 1994, T&G-4).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth